Go to PegaPoll
PEGAPOLL · NEWS

Sanofi’s prolonged Pompe drug shortage disrupts patient treatment

CNBC Top News · 2026-11-19
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.

Sanofi’s shortage of Pompe disease treatments has continued for more than three months, leading to canceled infusions for some patients who depend on Lumizyme or Nexviazyme every two weeks. The company says shipping delays could disrupt treatment for some U.S. patients through the end of November, although supply has begun improving in certain countries. Sanofi maintains that the medicines meet quality standards and has urged patients to consult healthcare professionals before switching, warning that the treatments are not interchangeable.

Pompe disease affects about one in 19,000 babies. Patients lack an enzyme needed to break down glycogen, causing the substance to accumulate in cells and progressively weaken muscles; it can also enlarge the heart and impair breathing and eating. Sanofi’s enzyme-replacement therapies are therefore a critical part of care, particularly for children and adults whose health depends on regular infusions.

Sanofi attributes the disruption to problems at its manufacturing facility in Ireland. The FDA inspected the plant from January 12 to January 20, 2026, found violations involving two unrelated drugs, and sent a warning letter on June 22 saying the company had not addressed an underlying manufacturing failure. Sanofi said resolving the FDA’s concerns contributed to the Pompe supply problems. Patients and advocates have criticized the company for not warning the community early enough, while the FDA says ensuring access is a priority and that it has offered assistance.

Continue in the app — vote & join in ➔
Source: CNBC Top News · via ahirlevel.hu

Related news